DOI: 10.1002/alr.70244 ISSN: 2042-6976

Intranasal Azelastine for Recurrent Acute Rhinosinusitis Prophylaxis: A Multicenter Retrospective Study

Akshay R. Prabhakar, Justina R. Varghese, William Marshall, Utkarsh Singh, Jake Hacker, Yixuan J. Zheng, Samuel E. Razmi, Ron L. Moses, Chadi A. Makary, Masayoshi Takashima, Omar G. Ahmed
Show PDF Cite

Key Points

Self‐controlled analysis: mean episodes reduced from 2.72 to 1.18 per year; 56.6% reduction.

Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS).

Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS).

More from our Archive